Brain Cancer

Press release from Oncoceutics curated by Executive Director Erika Vial Monteverdi.

The U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the drug ONC201 for treating a type of brain tumor known as “H3 K27M-mutant glioma,” which is primarily found in children. Alongside the Musella Foundation For Brain Tumor Research & Information, Inc, and the company xCures, Cancer Commons has been supporting this program to help patients in need.

Go to full article published by Novocure on Business Wire.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes: 

Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.

Go to full article published by Novocure on Business Wire.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by MedPage Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Research paper from Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

The best chance a patient has for survival with glioblastoma is the extent to which the tumor is initially removed surgically. The tools discussed in this study can help the surgeon maximize extirpation.

Go to full paper published in Neurosurgery.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

A large, retrospective study demonstrates that surgical removal of as much tumor tissue as possible results in the best outcomes for patients—seems pretty logical, and is true.

Go to full article published by MedPage Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Academic research paper from Clinical Epigenetics curated by Editor in Chief George Lundberg, MD, who notes: 

Brain tumor treatment decisions may be improved by integrating methylation-based tumor classification into the diagnosis process. Methylation refers to specific chemical features of tumor DNA that may impact how well different treatments might work.

Go to full academic research paper from Clinical Epigenetics.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Clinical OMICs curated by Editor in Chief George Lundberg, MD, who notes: 

Researchers have recently demonstrated a noninvasive way to diagnose and classify brain tumors using a blood test. This promising “liquid biopsy” method detects cell-free tumor DNA in the blood and analyzes its chemical features—specifically, its “methylation patterns”—with high sensitivity and accuracy. Such a test could help guide treatment decisions.

Go to full article published by Clinical OMICs.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The Pathologist curated by Editor in Chief George Lundberg, MD, who notes: 

Liquid biopsy shows surprising apparent prognostic value in glioblastoma multiforme (GBM).

Go to full article published by The Pathologist.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Announcement from the College of American Pathologists curated by Editor in Chief George Lundberg, MD, who notes: 

What forms of testing should be done for diffuse gliomas? In this announcement, a global panel invites comments about proposals.

Go to full announcement published by the College of American Pathologists.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Excerpt:

“Researchers at UCSF Benioff Children’s Hospitals are using next-generation genomic technology to develop targeted therapies for high-grade pediatric glioma.

“Sabine Mueller, MD, PhD, adjunct associate professor of neurology, pediatrics and neurosurgery at University of California, San Francisco, and colleagues aim to treat as many as 44 children and young adults with this disease.”

Go to full article published by Healio on Feb 3, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Excerpt from The ASCO Post:

“In a phase II trial funded by the European Organisation for Research and Treatment of Cancer and reported in The Lancet Oncology, van den Bent et al found no evidence of a survival benefit with the addition of bevacizumab (Avastin) to temozolomide in patients with a first recurrence of World Health Organization grade II or III glioma without the 1p/19q codeletion.

“In the open-label trial, conducted at 32 European centers, 155 patients were randomized between February 2011 and July 2015 to receive either temozolomide at 150 to 200 mg/m² on days 1 to 5 every 4 weeks for a maximum of 12 cycles (n = 77) or the same temozolomide regimen plus bevacizumab at 10 mg/kg every 2 weeks until disease progression (n = 78). Previous chemotherapy must have been stopped at least 6 months before enrollment, and radiotherapy, at least 3 months before enrollment. Overall, 44% of patients in the combination group and 47% in the temozolomide group had grade III disease.”

Go to full article published by The ASCO Post on Aug 20, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Excerpt from Targeted Oncology:

“The first patient has been dosed in a phase I/II open-label, multicenter trial investigating a novel immunotherapy combination in patients with newly diagnosed glioblastoma (GBM). Fifty patients have been accrued in the trial, as of May 31, 2018, which will be conducted at 25 sites across the nation.

“This study aims to investigate the efficacy of INO-5401, a T-cell activating immunotherapy agent encoding multiple antigens in GBM, and INO-9012, an immune activator encoding IL-12, in combination with the PD-1 inhibitor cemiplimab (REGN2810).”

Go to full article published by Targeted Oncology on July 9, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from Michigan Health Lab curated by Editor in Chief George Lundberg, MD, who notes: 

Children with serious brain tumors need access to as many clinical trials as possible. This new consortium will encourage that.

Go to full article published by Michigan Health Lab.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Curated by Editor in Chief George Lundberg, MD:

Receiving a brain tumor diagnosis can be shocking for patients and their families. The Musella Foundation’s free “Brain Tumor Guide for the Newly Diagnosed” provides up-to-date guidance for people in this difficult position.

.

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

Go to full article published by ASCO Daily News.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from The Philadelphia Inquirer curated by Editor in Chief George Lundberg, MD, who notes: 

A new Pennsylvania law requires insurance coverage for use of FDA-approved best drugs first, rather than only after failing with a cheaper alternative.

Go to full article published by The Philadelphia Inquirer.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Research paper from Nature curated by Editor in Chief George Lundberg, MD, who notes: 

A massive study of thousands of cancers that explores the genomic basis for cancer is being reported simultaneously in dozens of journals. Nature has published this summary article.

Go to full paper published in Nature.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

During the COVID-19 pandemic, some clinical trials have gone virtual.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Excerpt from a National Geographic article:

“For now, the sole intervention for vulnerable cancer patients is social distancing and enhanced hygiene practices for their family and health care workers.”

Go to full article published by National Geographic.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Article from the American Society of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

For now, the only definite preventive measures vulnerable patients with cancer can use for themselves and their families are scrupulous social distancing and enhanced personal hygiene; i.e., wash your hands. For more details, ASCO is an authoritative source:

Go to full article published by the American Society of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.